| Revision as of 21:09, 10 November 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,084 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'DrugBank', 'ChEMBL').← Previous edit | Revision as of 21:10, 10 November 2011 edit undoBeetstra (talk | contribs)Edit filter managers, Administrators172,084 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: '').Next edit → | ||
| Line 35: | Line 35: | ||
| | PubChem = 83898 | | PubChem = 83898 | ||
| | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | ||
| | DrugBank = |
| DrugBank = APRD00224 | ||
| | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ||
| | ChemSpiderID = 75707 | | ChemSpiderID = 75707 | ||
| Line 43: | Line 43: | ||
| | KEGG = D07667 | | KEGG = D07667 | ||
| | ChEMBL_Ref = {{ebicite|changed|EBI}} | | ChEMBL_Ref = {{ebicite|changed|EBI}} | ||
| | ChEMBL = |
| ChEMBL = 1201267 | ||
| <!--Chemical data--> | |||
| | C=10 | H=17 | N=1 | O=1 | S=1 | | C=10 | H=17 | N=1 | O=1 | S=1 | ||
| | molecular_weight = 489.565 g/mol | | molecular_weight = 489.565 g/mol | ||
Revision as of 21:10, 10 November 2011
Pharmaceutical compound | |
 | |
| Clinical data | |
|---|---|
| Trade names | Evoxac |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a608025 |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | < 20% |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H17NOS |
| Molar mass | 489.565 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (what is this?) (verify) | |
Cevimeline (Evoxac) is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors. It is used in the treatment of dry mouth associated with Sjögren's syndrome.
Mechanism of action
By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.
Side effects
Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping.
Contraindications include asthma and angle closure glaucoma.
References
- Ono M, Takamura E, Shinozaki K; et al. (2004). "Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study". Am. J. Ophthalmol. 138 (1): 6–17. doi:10.1016/j.ajo.2004.02.010. PMID 15234277.
{{cite journal}}: Explicit use of et al. in:|author=(help); Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - MedicineNet: Cevimeline. Accessed 10/12/2007